Brown Cory D, Parnell Nolie K, Schulman Rhonda L, Brown Cassandra G, Glickman Nita W, Glickman Larry
Department of Veterinary Clinical Science, School of Veterinary Medicine, Purdue University, West Lafayette, IN 47907, USA.
J Am Vet Med Assoc. 2006 Jul 1;229(1):87-91. doi: 10.2460/javma.229.1.87.
To evaluate the clinicopathologic features, response to treatment, and risk factors associated with idiopathic neutropenia in dogs.
Retrospective case series.
11 dogs.
Medical records of dogs with idiopathic neutropenia were reviewed. Signalment, history, clinical signs, and response to treatment were recorded and compared with that in dogs with neutropenia attributable to known causes and to dogs without neutropenia (controls).
Compared with dogs with neutropenia attributable to known causes, dogs with idiopathic neutropenia had lower neutrophil counts and were younger. When compared with control dogs, age < 4 years was identified as a risk factor for developing idiopathic neutropenia. In all dogs with idiopathic neutropenia, remission of neutropenia occurred within 18 days after administration of prednisone (2 to 4 mg/kg [0.9 to 1.8 mg/lb], PO, daily) and no serious complications or infections developed.
An immune-mediated pathogenesis should be considered for dogs with idiopathic neutropenia in which the cause is not known. Severe neutropenia and young age were significantly associated with idiopathic neutropenia in dogs. Prognosis appeared to be excellent with prednisone treatment.
评估犬特发性中性粒细胞减少症的临床病理特征、治疗反应及相关危险因素。
回顾性病例系列研究。
11只犬。
回顾特发性中性粒细胞减少症犬的病历。记录品种、病史、临床症状及治疗反应,并与已知病因所致中性粒细胞减少症犬和无中性粒细胞减少症犬(对照组)进行比较。
与已知病因所致中性粒细胞减少症犬相比,特发性中性粒细胞减少症犬的中性粒细胞计数更低且年龄更小。与对照犬相比,年龄<4岁被确定为发生特发性中性粒细胞减少症的危险因素。在所有特发性中性粒细胞减少症犬中,给予泼尼松(2至4mg/kg[0.9至1.8mg/lb],口服,每日)后18天内中性粒细胞减少症缓解,且未发生严重并发症或感染。
对于病因不明的特发性中性粒细胞减少症犬,应考虑免疫介导的发病机制。严重中性粒细胞减少症和年轻与犬特发性中性粒细胞减少症显著相关。泼尼松治疗的预后似乎良好。